WilmerHale

The ‘strong, very experienced team’ at WilmerHale delivers advice across a broad variety of transactional matters, including stock-for-stock mergers, cash mergers, and joint ventures, frequently leveraging its significant cross-border capabilities to advise on multijurisdictional M&A. Located in Boston, Hal Leibowitz and Joseph Conahan co-chair the practice and specialize in representing buyers, sellers, and boards of directors in joint ventures and securities law matters. In New York, Andy Alin regularly acts on behalf of financial tech companies and private equity sponsors, Chris Barnstable-Brown focuses on the tech and life science sectors, and Mike Gilligan is well-versed with providing buy-side as well as sell-side advice on transactional matters. In Washington DC, Stephanie Evans is knowledgeable on strategic alliances, while Denver’s Kieth Trammell acts on behalf of acquirers and buyout funds. In New York, Tal Hacohen is a further name to note, and Andrew Bonnes stands out for public company counseling and divestitures from Boston.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘IN my experience, the M&A team around Tal Hacohen did an excellent job in supporting our needs in the US, across many disciplines (corporate, labor, finance, tax). Tal was able to corral the resources within the firm to provide a timely, holistic and comprehensive solution to the client.’
‘We are pleased to work with and recommend Keith Trammell. Keith is one of the most commercial and business savvy lawyers that we have worked with, helping identify key risks and, more importantly, finding solutions. He has shown appropriate "bedside" manners to reach great outcomes with both founders and sophisticated M&A professionals alike. ’
‘Strong, very experienced team that is responsive and timely. We work with an all-female team.’
‘Chalyse Robinson is top notch. Deep knowledge, very responsive, reliable, easy to work with.’
‘WilmerHale helped us scale our business from inception through multiple rounds of funding to successful acquisition by Instacart. They are thought partners and strategic advisors. I highly recommend them to founders and entrepreneurs that are looking for a firm that will nourish and defend their vision. We would not be where we are today without the guidance and support of WilmerHale.’
‘Tal Hacohen on the the M&A team at WilmerHale is exceptional. He provided strategic guidance and tactical execution through our successful acquisition by Instacart. What I valued most about Tal is how he acted as an extension of our executive leadership team. He is a joy and a pleasure to collaborate with. His team's work ethic and diligence knows no bounds. I look forward to the opportunity to partnering with Tal and WH again in the future.’
‘Extreme ownership with lean deal teams provides sense of accountability.’
‘Tal Hacohen was extremely creative and thoughtful in devising a solution for a tough M&A deal. These were issues that don't come up often and he was a great partner to brainstorm with on a creative solution in order to keep the deal alive and progressing.’

Key clients

Revvity (FKA PerkinElmer, Inc.)
AdoreMe, Inc.
Casella Waste Systems
Verde Bioresins
Carisma Therapeutics, Inc.
Infinity Pharmaceuticals, Inc.
Blue Apron Holdings, Inc.
SDC Capital Partners, LLC
Gemini Therapeutics
State Street Corporation
Nabriva Therapeutics
Solid Biosciences
SecZetta
AVEO Oncology
Akouos, Inc.
Decibel Therapeutics
IMARA Inc.
TMX Group
EverQupte
Editas Medicine
Mountaingate Capital
Stirista, LLC
Pragma Weeden Holdings LLC

Work highlights

Represented Revvity (FKA PerkinElmer), in its agreement to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital, a leading growth-oriented private equity firm, for $2.45 billion.
Represented AdoreMe, Inc., in connection with its sale to Victoria’s Secret & Co. for an upfront $390 million cash payment and deferred cash payments of between $100 million and $300 million, contingent on the post-closing financial performance of AdoreMe and the achievement of specified milestones related to realizing technological synergies.
Represented AVEO Oncology in its sale to LG Chem in an all-cash transaction with an implied equity value of approximately $566 million.